Developed in BC: Potential prostate cancer treatment

Issue: BCMJ, vol. 58, No. 1, January February 2016, Pages 41-42 News

A potential treatment for advanced prostate cancer developed by UBC and Vancouver Coastal Health Research Institute (VCHRI) scientists has been licensed to pharmaceutical company Roche to help move the technology into a finished product. Developed at the Vancouver Prostate Centre, the new drug technology (now in preclinical development) could one day be used to treat prostate cancers that have become resistant to existing treatments. When advanced prostate cancer spreads it becomes metastatic and virtually incurable. Current treatments initially slow the spread of the disease and help prolong a patient’s life, but the cancer eventually mutates and becomes resistant to drugs. The potential new treatment, developed using a computer technology that can scan a database of millions of different molecules to find the ones that will work best as possible treatments, is designed to target a site in the cancer cells that is not prone to mutation.

Research will continue in collaboration with the scientists at the Vancouver Prostate Centre, a research hub hosted by UBC and VCHRI and designated a national Centre of Excellence for Commercialization and Research. The research was funded in part by Prostate Cancer Canada, Prostate Cancer Foundation (US), Safeway Canada, the CIHR’s Proof of Principle commercialization program, and PC-TRiADD.

For more information about the Vancouver Prostate Centre’s research initiatives, visit

. Developed in BC: Potential prostate cancer treatment. BCMJ, Vol. 58, No. 1, January, February, 2016, Page(s) 41-42 - News.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply